51
Participants
Start Date
March 31, 2009
Primary Completion Date
September 30, 2013
Study Completion Date
December 31, 2015
LBH589
bevacizumab
University of Virginia, Department of Neurology, Charlottesville
Northwestern University, Chicago
Massachusetts General Hospital, Boston
Beth-Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Collaborators (2)
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Northwestern University
OTHER
University of Virginia
OTHER
Genentech, Inc.
INDUSTRY
Novartis
INDUSTRY
Patrick Y. Wen, MD
OTHER